Lundbeck CEO: two to three projects will fail every year
We might as well get used to it: There will be a greater number of failed studies from Lundbeck in the time to come. But the company has time to wait for the winning ticket as sales of its key products are on the rise – and with years of patent protection ahead, CEO Kåre Schultz is playing it cool.
BY LOUISE WENDT JENSEN
In late September, Denmark’s Lundbeck saw one of its major pipeline hopes, idalopirdine, fail in a phase III trial in patients with Alzheimer’s disease – the first of three pivotal studies. And the setback has taken its toll on the group’s finances, it said in its interim report for Q3 on Wednesday.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
FDA approves new epilepsy drug from Lundbeck
For abonnenter
